Soquelitinib

The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition.

NIH/NIAID has launched a Phase 2 clinical trial of Corvus Pharmaceuticals' soquelitinib for autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease typically manifesting by age two.

Corvus Pharmaceuticals' Phase 1 trial of soquelitinib for atopic dermatitis shows a favorable safety and efficacy profile.

Corvus Pharmaceuticals is progressing Phase 3 trials for soquelitinib in Peripheral T Cell Lymphoma (PTCL) and Phase 1 trials for atopic dermatitis, with interim data expected in December 2024.

New data suggests ciforadenant, an adenosine A2A receptor antagonist, can overcome resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).